Celgene (NASDAQ:CELG) was upgraded by equities research analysts at Atlantic Securities from a “neutral” rating to an “overweight” rating in a research report issued on Friday.

CELG has been the topic of a number of other research reports. Vetr cut shares of Celgene from a “strong-buy” rating to a “buy” rating and set a $146.88 price objective on the stock. in a research note on Tuesday, August 29th. Royal Bank Of Canada dropped their price objective on shares of Celgene from $166.00 to $148.00 and set a “top pick” rating on the stock in a research note on Friday, October 27th. Leerink Swann reaffirmed a “buy” rating and set a $156.00 price objective on shares of Celgene in a research note on Friday, October 20th. Morgan Stanley dropped their price objective on shares of Celgene from $120.00 to $115.00 and set an “underweight” rating on the stock in a research note on Monday, October 23rd. Finally, Cantor Fitzgerald reaffirmed a “buy” rating on shares of Celgene in a research note on Monday, August 28th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twenty have issued a buy rating and two have given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $139.57.

Celgene (NASDAQ:CELG) opened at $106.09 on Friday. Celgene has a fifty-two week low of $94.55 and a fifty-two week high of $147.17. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. The firm has a market cap of $83,526.46, a P/E ratio of 16.58, a P/E/G ratio of 0.82 and a beta of 1.78.

Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping analysts’ consensus estimates of $1.87 by $0.04. The business had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The business’s revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the company earned $1.58 EPS. analysts expect that Celgene will post 6.67 earnings per share for the current year.

In other news, Director Gilla Kaplan sold 9,250 shares of Celgene stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the transaction, the director now owns 85,551 shares in the company, valued at approximately $12,110,599.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Terrie Curran sold 1,727 shares of Celgene stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the transaction, the insider now owns 3,925 shares in the company, valued at approximately $564,768.25. The disclosure for this sale can be found here. Company insiders own 0.95% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. grew its position in Celgene by 5.7% in the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after acquiring an additional 3,084,227 shares in the last quarter. Vanguard Group Inc. grew its position in Celgene by 3.1% in the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after acquiring an additional 1,610,056 shares in the last quarter. State Street Corp grew its position in Celgene by 2.3% in the 1st quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after acquiring an additional 723,844 shares in the last quarter. Jennison Associates LLC grew its position in Celgene by 11.5% in the 3rd quarter. Jennison Associates LLC now owns 14,962,407 shares of the biopharmaceutical company’s stock valued at $2,181,818,000 after acquiring an additional 1,546,673 shares in the last quarter. Finally, FMR LLC grew its position in Celgene by 5.9% in the 2nd quarter. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company’s stock valued at $1,635,643,000 after acquiring an additional 697,250 shares in the last quarter. Institutional investors and hedge funds own 80.17% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Celgene (CELG) Stock Rating Upgraded by Atlantic Securities” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/12/10/celgene-celg-stock-rating-upgraded-by-atlantic-securities.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related stocks with our FREE daily email newsletter.